Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study

17 Mar 2024

Abstract excerpt

BACKGROUND: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics and Drug Metabolism
Share to Schizophrenia research and treatment
Share to Tryptophan and brain disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38494658
DOI: 10.1177/02698811241238283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional StudyPMID 38494658Read ↗

Pharmacogenetics-Guided Advances in Antipsychotic Treatment.Semantic proximity Read ↗

Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic TreatmentsSemantic proximity Read ↗

Clinical effects of CYP2D6 phenoconversion in patients with psychosis.Semantic proximity Read ↗

Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.Semantic proximity Read ↗

GENETIC VARIANTS IN ANTIPSYCHOTIC METABOLISM: POLYMORPHISM PROFILES IN KAZAKH COHORT WITH PARANOID SCHIZOPHRENIA.Semantic proximity Read ↗

Pharmacogenetics of antipsychotics: Clinical utility and implementationSemantic proximity Read ↗

Real-World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children.Semantic proximity Read ↗

Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.Semantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.Semantic proximity Read ↗

Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant SchizophreniaSemantic proximity Read ↗

Pharmacogenetics of AntipsychoticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.